Company intelligence / Profile preview

Materia Medica Holding

Moscow, Moscow, Russia

Ownership: Private
Employees: ~1400
Development stage: Commercial

Overview

Materia Medica is one of Russia’s top pharmaceutical companies with over thirty medications on the market. The firm is recognized for pioneering research into ultra-low dose antibody drugs. Its portfolio includes original products for viral infections, neurology/psychiatry disorders, urogenital health, rheumatology/joint disease, alcohol dependence treatment and more. Products are sold across Russia/CIS/EU/Asia/Latin America. The company has received multiple national awards for innovation and product quality.

Therapeutic areas: Men's HealthPulmonologyMetabolic DisordersImmunologyPsychiatryRheumatologyInfectious Diseases
Modalities: Small moleculesUltra-low dose antibodies ("activated" antibodies)
Industry: Biotech

Drug pipeline

1 asset

Subetta

Partnerships

Partnered with various Russian/international clinics for clinical research; no major global pharma partnerships disclosed.

Beyond the preview

Go deeper on Materia Medica Holding.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Materia Medica Holding.

Explore the full profile